{"entity":{"id":"nct04086264","kind":"trial","name":"IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia","aka":[],"tldr":"A phase 1/2 trial of Azacitidine, Pivekimab sunirine and Venetoclax in acute myeloid leukaemia, run by AbbVie, active and no longer recruiting.","summary":"IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia is a phase 1/2 interventional study registered as NCT04086264 by AbbVie, with 218 participants enrolled, started 2019-11-06 and due to reach its primary completion in 2027-02. Interventions recorded: Azacitidine, IMGN632 and Venetoclax.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04086264","url":"https://clinicaltrials.gov/study/NCT04086264"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["aml"],"sections":[],"technologies":[],"targets":[],"drugs":["azacitidine","pivekimab-sunirine","venetoclax"],"companies":["abbvie"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04086264","phase":"1/2","setting":"A Phase 1b/2 Study of IMGN632 as Monotherapy or Combination With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia","sponsor":"AbbVie","enrolled":218,"outcomes":[]},"route":"/trials/nct04086264/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"}],"drug":[{"id":"azacitidine","kind":"drug","name":"Azacitidine","route":"/drugs/azacitidine/"},{"id":"pivekimab-sunirine","kind":"drug","name":"Pivekimab sunirine","route":"/drugs/pivekimab-sunirine/"},{"id":"venetoclax","kind":"drug","name":"Venetoclax","route":"/drugs/venetoclax/"}],"company":[{"id":"abbvie","kind":"company","name":"AbbVie (incl. ImmunoGen, Capstan)","route":"/companies/abbvie/"}]}}